Literature DB >> 23290496

Selective knockout of the casein kinase 2 in d1 medium spiny neurons controls dopaminergic function.

Heike Rebholz1, Mingming Zhou, Angus C Nairn, Paul Greengard, Marc Flajolet.   

Abstract

BACKGROUND: Dopamine, crucial for the regulation of motor function and reward, acts through receptors mainly expressed in striatum as well as cortex. Dysregulation of dopaminergic signaling is associated with various neuropsychiatric disorders. Consequently, dopamine-regulating drugs are effectively used in treating these disorders, such as L-DOPA for Parkinson's disease, methylphenidate for attention-deficit/hyperactivity disorder, or antipsychotics for schizophrenia. As a result, there has been much interest in dissecting signaling networks in the two morphologically indistinguishable D1- and D2-receptor-expressing medium spiny neurons. Our previous results highlighted a role for casein kinase 2 (CK2) in the modulation of dopamine D1 receptor (D1R) signaling in cells.
METHODS: To study the importance of CK2 in vivo, we have selectively knocked out CK2, in either D1- or D2-medium spiny neurons (MSNs) and characterized the mice behaviorally and biochemically (n = 4-18).
RESULTS: The D1-MSN knockout mice exhibited distinct behavioral phenotypes including novelty-induced hyperlocomotion and exploratory behavior, defective motor control, and motor learning. All of these behavioral traits are indicative of dysregulated dopamine signaling and the underlying mechanism appears to be an alteration of D1R signaling. In support of this hypothesis, D1R levels were upregulated in the knockout mice, as well as phosphorylation of DARPP-32 (dopamine- and cyclic adenosine monophosphate [cAMP]-regulated phospho-protein of 32 kDa), most of the behavioral phenotypes were abolished by the D1R antagonist, SCH23390, and the D2-MSN knockout mice displayed no obvious behavioral phenotype.
CONCLUSIONS: A single kinase, CK2, in D1-MSNs significantly alters dopamine signaling, a finding that could have therapeutic implications for disorders characterized by dopamine imbalance such as Parkinson's disease, attention-deficit/hyperactivity disorder, and schizophrenia.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23290496      PMCID: PMC3878430          DOI: 10.1016/j.biopsych.2012.11.013

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  54 in total

1.  Paradoxical locomotor behavior of dopamine D1 receptor transgenic mice.

Authors:  S Dracheva; M Xu; K A Kelley; V Haroutunian; G R Holstein; S Haun; J H Silverstein; S C Sealfon
Journal:  Exp Neurol       Date:  1999-05       Impact factor: 5.330

2.  Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study.

Authors:  Jeffrey H Meyer; Heather E McNeely; Sandra Sagrati; Anahita Boovariwala; Krystle Martin; N Paul L G Verhoeff; Alan A Wilson; Sylvain Houle
Journal:  Am J Psychiatry       Date:  2006-09       Impact factor: 18.112

3.  A CamKIIalpha iCre BAC allows brain-specific gene inactivation.

Authors:  E Casanova; S Fehsenfeld; T Mantamadiotis; T Lemberger; E Greiner; A F Stewart; G Schütz
Journal:  Genesis       Date:  2001-09       Impact factor: 2.487

4.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus.

Authors:  H C Hemmings; A C Nairn; D W Aswad; P Greengard
Journal:  J Neurosci       Date:  1984-01       Impact factor: 6.167

Review 5.  The neurobiology of slow synaptic transmission.

Authors:  P Greengard
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

6.  CK2 negatively regulates Galphas signaling.

Authors:  Heike Rebholz; Akinori Nishi; Sabine Liebscher; Angus C Nairn; Marc Flajolet; Paul Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

7.  Globozoospermia in mice lacking the casein kinase II alpha' catalytic subunit.

Authors:  X Xu; P A Toselli; L D Russell; D C Seldin
Journal:  Nat Genet       Date:  1999-09       Impact factor: 38.330

8.  Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II.

Authors:  J A Girault; H C Hemmings; K R Williams; A C Nairn; P Greengard
Journal:  J Biol Chem       Date:  1989-12-25       Impact factor: 5.157

9.  Tissue distribution of casein kinases.

Authors:  S Nakajo; T Hagiwara; K Nakaya; Y Nakamura
Journal:  Biochem Int       Date:  1987-01

10.  Selective deletion of the leptin receptor in dopamine neurons produces anxiogenic-like behavior and increases dopaminergic activity in amygdala.

Authors:  J Liu; S M Perez; W Zhang; D J Lodge; X-Y Lu
Journal:  Mol Psychiatry       Date:  2011-04-12       Impact factor: 15.992

View more
  14 in total

1.  Okur-Chung neurodevelopmental syndrome-linked CK2α variants have reduced kinase activity.

Authors:  I Dominguez; J M Cruz-Gamero; V Corasolla; N Dacher; S Rangasamy; A Urbani; V Narayanan; H Rebholz
Journal:  Hum Genet       Date:  2021-05-04       Impact factor: 4.132

2.  CK2 regulates 5-HT4 receptor signaling and modulates depressive-like behavior.

Authors:  J Castello; B LeFrancois; M Flajolet; P Greengard; E Friedman; H Rebholz
Journal:  Mol Psychiatry       Date:  2017-11-21       Impact factor: 15.992

3.  CK2 Controls Th17 and Regulatory T Cell Differentiation Through Inhibition of FoxO1.

Authors:  Sara A Gibson; Wei Yang; Zhaoqi Yan; Hongwei Qin; Etty N Benveniste
Journal:  J Immunol       Date:  2018-06-11       Impact factor: 5.422

4.  Conditional targeting of medium spiny neurons in the striatal matrix.

Authors:  Björn Reinius; Martina Blunder; Frances M Brett; Anders Eriksson; Kalicharan Patra; Jörgen Jonsson; Elena Jazin; Klas Kullander
Journal:  Front Behav Neurosci       Date:  2015-03-27       Impact factor: 3.558

Review 5.  CK2-An Emerging Target for Neurological and Psychiatric Disorders.

Authors:  Julia Castello; Andre Ragnauth; Eitan Friedman; Heike Rebholz
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-05

6.  Myeloid Cell CK2 Regulates Inflammation and Resistance to Bacterial Infection.

Authors:  Sandy R Larson; Nikki Bortell; Alysha Illies; William J Crisler; Jennifer L Matsuda; Laurel L Lenz
Journal:  Front Immunol       Date:  2020-12-08       Impact factor: 7.561

7.  Protein Kinase CK2 Regulates B Cell Development and Differentiation.

Authors:  Hairong Wei; Wei Yang; Huixian Hong; Zhaoqi Yan; Hongwei Qin; Etty N Benveniste
Journal:  J Immunol       Date:  2021-07-23       Impact factor: 5.426

8.  Pathogenesis of cardiac ischemia reperfusion injury is associated with CK2α-disturbed mitochondrial homeostasis via suppression of FUNDC1-related mitophagy.

Authors:  Hao Zhou; Pingjun Zhu; Jin Wang; Hong Zhu; Jun Ren; Yundai Chen
Journal:  Cell Death Differ       Date:  2018-03-14       Impact factor: 15.828

9.  Functional association between NUCKS1 gene and Parkinson disease: A potential susceptibility biomarker.

Authors:  Sarita Singh; Prahlad Kishore Seth
Journal:  Bioinformation       Date:  2019-09-05

10.  Phosphorylation of Syntaxin-1a by casein kinase 2α regulates pre-synaptic vesicle exocytosis from the reserve pool.

Authors:  Vanilla Hua Shi; Tim J Craig; Paul Bishop; Yasuko Nakamura; Dan Rocca; Kevin A Wilkinson; Jeremy M Henley
Journal:  J Neurochem       Date:  2020-09-06       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.